Clinical Trial Update: Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases. [Phase 2]

View source ↗

Summary

Phase 2 trial of denosumab in combination with enzalutamide in progressive metastatic castration-resistant prostate cancer with bone metastases was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Denosumab (denosumab)
• Enzalutamide (enzalutamide)

Snippet

Sponsor: Cancer Trials Ireland | Conditions: Castration-resistant Prostate Cancer, Metastatic Cancer | Phase 2 | Status: TERMINATED